Elaphron has completed an INTERACT meeting with the U.S. Food and Drug Administration (FDA) regarding EL-924, its lead gut-localized therapeutic candidate for obesity and metabolic dysfunction.
The interaction provided important regulatory alignment on a potentially streamlined development strategy for EL-924. FDA indicated that it was open to allowing reliance on the 505(b)(2) pathway for substantial portions of the development program, where scientifically appropriate, potentially allowing Elaphron to leverage the extensive existing human safety experience associated with EL-924’s constituent components rather than unnecessarily duplicating established safety information.
Importantly, FDA raised no fundamental objections to the proposed development strategy and provided feedback that could meaningfully reduce the scope, cost, and duration of the program required to advance EL-924 into clinical development.
A More Capital-Efficient Development Path
Based on the INTERACT feedback, Elaphron believes the EL-924 development program may benefit from several important efficiencies:
~50% lower IND-enabling toxicology burden
FDA indicated that a single-species repeat-dose toxicology program may be acceptable for this locally acting, minimally absorbed therapeutic approach, subject to final study design and regulatory agreement.
Reduced PK and ADME requirements
FDA was open to reliance on existing published safety information where scientifically justified, potentially reducing the need to reproduce portions of the conventional systemic drug-development package.
505(b)(2) regulatory flexibility
The potential ability to rely on decades of human safety experience with previously characterized constituents provides an established safety foundation for portions of the EL-924 development program while Elaphron generates the new data required for the novel product.
Major CMC activities shifted toward later-stage development
FDA feedback allows substantial elements of the CMC program to be addressed later in development, reducing the capital and execution burden required before initial clinical studies.
Together, these efficiencies could potentially shorten development by approximately 12–18 months compared with a conventional full development program, while substantially reducing the capital required to reach early human proof-of-concept.
De-Risking the Path to the Clinic
The INTERACT outcome represents an important regulatory milestone for EL-924. It provides Elaphron with a clearer, potentially faster and more capital-efficient path toward IND submission and first-in-human clinical development while preserving the scientific and safety standards required for a novel metabolic therapy.
For Elaphron, this is particularly important: our strategy is not only to develop differentiated biology, but to combine that innovation with a pragmatic regulatory pathway capable of translating promising science into medicines efficiently.